| Submit your comments on this article |
| Economy |
| Drug Companies ‘Fear-Mongering' to Resist Trump Administration Plan to Allow Import of Pharmaceutical Drugs |
| 2019-08-03 |
| [Epoch Times] The proposal to implement a pharmaceutical drug import plan by the Trump administration is being met with opposition by drug makers and researchers who call the plan a dangerous scheme. But Marc-André Gagnon, a pharmaceutical policy researcher at Carleton University in Ontario, Canada, and Master of Advanced Studies in Economics, said he doesn’t buy into all the negativity. "There’s a bit of a fear-mongering campaign in Canada that this type of proposal will be a catastrophe, people will die, the pharmacy shelves will be empty," said Gagnon. "So it’s all about drug shortages in Canada." OR it's a move that will more evenly spread the costs past the American consumers. Why should foreigners receive discounts while the citizens of the country that created the drugs pay more? "Because they can" The proposed program would allow states, pharmacies, and drug distributors to develop pilot programs to import drugs from other countries, primarily Canada. |
| Posted by:Besoeker |
| #4 I suspect Drug companies are a bit more afraid of the Democrat candidate plans at this point. |
| Posted by: ruprecht 2019-08-03 15:10 |
| #3 If done, then drug companies would raise prices on drugs sold elsewhere in order to maintain overall supply/demand/cost/price structure. |
| Posted by: Glenmore 2019-08-03 13:59 |
| #2 Thank you, Sock Puppet of Doom. The issue, as I am now seeing it from our slow motion discussion, is the difference of approach between accounting and return on investment. What think you of this: Return on investment falls for pharmaceutical industry |
| Posted by: trailing wife 2019-08-03 10:56 |
| #1 This is for TW Yes R&D can run into the billions however you can carry forward losses to protect future profits on successful drugs The point is that GAAP says R&D is a sunk cost and should not be used to determine the costs of the drug. If you spent 200 million in R&D on drug x in 2013, it has been deducted or recouped in tax deductions so that it should not be used as a cost when the drug goes to market in 2019. R&D is annualized and deducted every year not cumulatively |
| Posted by: Sock Puppet of Doom 2019-08-03 08:16 |